Completed PHASE2 INTERVENTIONAL 3-arm NCT00568321

RN624 For Pain Of Post-Herpetic Neuralgia

A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP, PROOF OF CONCEPT STUDY OF THE ANALGESIC EFFECTS OF RN624 IN ADULT PATIENTS WITH POST-HERPETIC NEURALGIA

Sponsor: Pfizer

Conditions Neuralgia, Postherpetic

Interventions Placebo RN624

Updated 8 times since 2017 Last updated: May 5, 2021 Started: Dec 19, 2007 Primary completion: Dec 20, 2008 Completion: Jan 7, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neuralgia, Postherpetic, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altoona, United States , Ann Arbor, United States , Anniston, United States , Asheville, United States , Atlantis, United States , Bryan, United States , Clearwater, United States , Cleveland, United States , Dallas, United States , Dayton, United States and 17 more locations